ArticleACS nano2023
Nonviral
Abstract read
In one paragraph
Article in ACS nano, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Non-Viral CRISPR carriers: transient delivery with lasting effects.Drug delivery · 2026Review
- CRISPR/Cas‑based epigenome editing for osteogenic lineage commitment.Cell and tissue research · 2026Review
- Review
- Nanocarrier-mediated CRISPR-Cas delivery: a novel approach against antibiotic-resistant superbugs.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2026Review
- Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections.BMC medicine · 2025Review
- CRISPR-Cas9 in the Tailoring of Genetically Engineered Animals.Current issues in molecular biology · 2025Review
- Preclinical development of genome editing to treat Duchenne muscular dystrophy by exon skipping.Journal of neuromuscular diseases · 2025Review
- The Interface of Gene Editing with Regenerative Medicine.Engineering (Beijing, China) · 2025Article
- A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine.Osteoarthritis and cartilage · 2025Article
- Delivery of genetic medicines for muscular dystrophies.Cell reports. Medicine · 2025Review
- A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine.bioRxiv : the preprint server for biology · 2024Article
- Engineering approaches for RNA-based and cell-based osteoarthritis therapies.Nature reviews. Rheumatology · 2024Review
- The Current Situation and Development Prospect of Whole-Genome Screening.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
R Brock FletcherDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.ORCID 0000-0002-3986-9040
Larry D StokesDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Isom B KellyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Katelyn M HendersonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Isabel C Vallecillo-ViejoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Juan M ColazoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.ORCID 0000-0002-3591-4246
Benjamin V WongDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Fang YuDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Richard d'ArcyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Morgan N StruthersDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Brian C EvansDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Jacob AyersDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Matthew CastanonDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Michael J WeirichDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Sarah K ReillyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Shrusti S PatelDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Yoanna I IvanovaDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Carlos A Silvera BatistaDepartment of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.ORCID 0000-0002-3509-601X
Sharon M WeissDepartment of Electrical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.ORCID 0000-0003-2252-3104
Charles A GersbachDepartment of Biomedical Engineering, Duke University, Durham, North Carolina 27708, United States.ORCID 0000-0003-1478-4013
Jonathan M BrungerDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.
Craig L DuvallDepartment of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee 37235-1631, United States.ORCID 0000-0003-3979-0620
Funding
University Training Program in Biomolecular and Tissue EngineeringT32GM144291 · NIGMS · DUKE UNIVERSITY · PI Charles A. Gersbach, Tatiana Segura · 2022 to 2026
$2.6MNextGen RNAi Delivery to Breast Tumors for Selective mTORC2 BlockadeR01CA224241 · NCI · VANDERBILT UNIVERSITY · PI BRANTLEY-SIEDERS, DANA M, COOK, REBECCA SARA · 2018 to 2022
$2.5MEpigenome Editing Technologies for Treating Diverse DiseaseU01AI146356 · NIAID · DUKE UNIVERSITY · PI GERSBACH, CHARLES A. · 2019 to 2022
$1.6MVanderbilt Stimulating Access to Research in Residency (V-StARR)R38HL143619 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WEBBER, STEVEN A., WILLIAMS, CHRISTOPHER S. · 2018 to 2021
$1.3MAlbumin Binding siRNAs for Systemic Treatment of Multi-Joint OsteoarthritisR21AR078636 · NIAMS · VANDERBILT UNIVERSITY · PI DUVALL, CRAIG LEWIS · 2021 to 2022
$374kNCI NIH HHS R01 CA224241NHLBI NIH HHS R38 HL143619NIAID NIH HHS U01 AI146356NIAMS NIH HHS R21 AR078636NIGMS NIH HHS T32 GM144291
Abstract
The complexity of CRISPR machinery is a challenge to its application for nonviral
Indexed as
CRISPR-Cas SystemsNanoparticlesAnimalsMicePolymersPorositySiliconPolymersSiliconarthritisCRISPRDuchenne’s muscular dystrophyporous silicon nanoparticlesribonucleoprotein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.